Rafael Depetris

Rafael Depetris is a seasoned professional in biochemistry and structural biology, currently serving as the Director at Volastra Therapeutics since July 2022. Prior experience includes roles at Kadmon, a Sanofi Company, where Rafael advanced from Principal Scientist I to Principal Scientist II, leading structure-based drug design efforts over eight years. Previous positions include Senior Scientist at Pfizer's Centers for Therapeutic Innovation and Postdoctoral Associate at Weill Medical College of Cornell University, focusing on HIV-1 vaccine development. Educational credentials include a Ph.D. in Structural Biology from NYU Grossman School of Medicine and a Licentiate in Biology from the University of Buenos Aires.